Dr. Dimou on Emerging Treatment Options in BRAF+ Lung Cancer

Video

In Partnership With:

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Anastasios (Tassos) Dimou, MD, a medical oncologist at Mayo Clinic, discusses emerging treatment options in BRAF-positive lung cancer.

Standard chemotherapy and immunotherapy have demonstrated success in patients with BRAF-mutant lung cancer, explains Dimou.

Single-agent immunotherapy appears to elicit similar responses for patients with BRAF-mutant disease as it does for those in the general lung cancer population, says Dimou. Other oncogene-driven lung cancers have not shown similar responses with immunotherapy.

BRAF and MEK inhibitors that are approved in melanoma are also being actively investigated as targeted therapy in BRAF-driven lung cancer.

Although these agents have different safety profiles compared with current regimens, such as the combination of dabrafenib (Tafinlar) and trametinib (Mekinist), they could introduce more options for patients with BRAF-positive lung cancer, concludes Dimou.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD